Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

CONTEXT Evidence that rofecoxib increases the risk of myocardial infarction has led to scrutiny of other nonsteroidal anti-inflammatory drugs (NSAIDs). Regulatory agencies have provided variable advice regarding the cardiovascular risks with older nonselective NSAIDs. OBJECTIVE To undertake a systematic review and meta-analysis of controlled observational studies to compare the risks of serious cardiovascular events with individual NSAIDs and cyclooxygenase 2 inhibitors. DATA SOURCES Searches were conducted of electronic databases (1985-2006), scientific meeting proceedings, epidemiological research Web sites, and bibliographies of eligible studies. STUDY SELECTION Eligible studies were of case-control or cohort design, reported on cardiovascular events (predominantly myocardial infarction) with cyclooxygenase 2 inhibitor, NSAID use, or both with nonuse/remote use of the drugs as the reference exposure. Of 7086 potentially eligible titles, 17 case-control and 6 cohort studies were included. Thirteen studies reported on cyclooxygenase 2 inhibitors, 23 on NSAIDs, and 13 on both groups of drugs. DATA EXTRACTION Two people independently extracted data and assessed study quality with disagreements resolved by consensus. DATA SYNTHESIS Data were combined using a random-effects model. A dose-related risk was evident with rofecoxib, summary relative risk with 25 mg/d or less, 1.33 (95% confidence interval [CI], 1.00-1.79) and 2.19 (95% CI, 1.64-2.91) with more than 25 mg/d. The risk was elevated during the first month of treatment. Celecoxib was not associated with an elevated risk of vascular occlusion, summary relative risk 1.06 (95% CI, 0.91-1.23). Among older nonselective drugs, diclofenac had the highest risk with a summary relative risk of 1.40 (95% CI, 1.16-1.70). The other drugs had summary relative risks close to 1: naproxen, 0.97 (95% CI, 0.87-1.07); piroxicam, 1.06 (95% CI, 0.70-1.59); and ibuprofen, 1.07 (95% CI, 0.97-1.18). CONCLUSIONS This review confirms the findings from randomized trials regarding the risk of cardiovascular events with rofecoxib and suggests that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug.

[1]  H. Weiss,et al.  Effect of ibuprofen on cardioprotective effect of aspirin , 2003, The Lancet.

[2]  F. Tinahones,et al.  Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout , 2004, Annals of the rheumatic diseases.

[3]  J. Hallas,et al.  Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs: A Nested Case-Control Study , 2003, Stroke.

[4]  R. Schlienger,et al.  Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. , 2004, Archives of internal medicine.

[5]  R. Schlienger,et al.  Current Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction , 2005, Pharmacotherapy.

[6]  P. McGettigan,et al.  Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships. , 2006, British journal of clinical pharmacology.

[7]  James M Brophy,et al.  The Risk for Myocardial Infarction With Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults , 2005, Annals of internal medicine.

[8]  M. Feldman,et al.  Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. , 1998, The American journal of medicine.

[9]  D. Flum,et al.  Perioperative Rofecoxib Plus Local Anesthetic Field Block Diminishes Pain and Recovery Time After Outpatient Inguinal Hernia Repair , 2005, Anesthesia and analgesia.

[10]  Peter C Austin,et al.  Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. , 2003, Archives of internal medicine.

[11]  Daniel H Solomon,et al.  Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. , 2002, Archives of internal medicine.

[12]  C Michael Stein,et al.  Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study , 2002, The Lancet.

[13]  R. Tarone,et al.  Risks of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs , 2005 .

[14]  L. Køber,et al.  Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction , 2006, Circulation.

[15]  C. Patrono,et al.  Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. , 2001, The Journal of clinical investigation.

[16]  C Michael Stein,et al.  COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.

[17]  M. Aronson,et al.  Cardiovascular Risks of Cyclooxygenase-2 Inhibitors: Where We Stand Now , 2005, Annals of Internal Medicine.

[18]  C. Patrono,et al.  Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. , 2000, Epidemiology.

[19]  H. Kehlet,et al.  The Role of the Anesthesiologist in Fast-Track Surgery: From Multimodal Analgesia to Perioperative Medical Care , 2007, Anesthesia and analgesia.

[20]  Carol Coupland,et al.  Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.

[21]  M. Reilly,et al.  The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. , 2004, Journal of the American College of Cardiology.

[22]  S. Shoor,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study , 2005, The Lancet.

[23]  H. Sørensen,et al.  Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. , 2005, Archives of internal medicine.

[24]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[25]  B. Thiers.  Non-Steroidal Anti-inflammatory Drugs and the Risk of Oral Cancer: A Nested Case-Control Study , 2006 .

[26]  Lise,et al.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. , 2000, The New England journal of medicine.

[27]  J. Sudbø,et al.  RETRACTED: Non-steroidal anti-inflammatory drugs and the risk of oral cancer: a nested case-control study , 2005, The Lancet.

[28]  Parenteral ketorolac and risk of myocardial infarction , 2002, Pharmacoepidemiology and drug safety.

[29]  Sebastian Schneeweiss,et al.  Relationship Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults , 2004, Circulation.

[30]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[31]  H. Krumholz,et al.  Nonsteroidal antiinflammatory drugs after acute myocardial infarction. , 2002, American heart journal.

[32]  A. Maguire,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population , 2004, Circulation.

[33]  P. White,et al.  The Efficacy of Celecoxib Premedication on Postoperative Pain and Recovery Times After Ambulatory Surgery: A Dose-Ranging Study , 2003, Anesthesia and analgesia.

[34]  D. Graham,et al.  Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study , 2005 .

[35]  M. Egger,et al.  Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.

[36]  J. Brophy,et al.  Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors , 2006, Canadian Medical Association Journal.

[37]  H. Krumholz,et al.  Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study , 2003, BMJ : British Medical Journal.

[38]  Hershel Jick,et al.  Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. , 2002, British journal of clinical pharmacology.

[39]  H. Guess,et al.  Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. , 2002, Archives of internal medicine.

[40]  A. Gonzáléz-Pérez,et al.  Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population Brief title : NSAID chronic use and risk of myocardial infarction , 2005 .

[41]  B. Caldwell,et al.  Risk of Cardiovascular Events and Celecoxib: a Systematic Review and Meta-Analysis , 2006 .

[42]  M. Reilly,et al.  Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction , 2005, Annals of Internal Medicine.

[43]  T. Burnakis.  Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. , 2002, The New England journal of medicine.